On Wednesday, 20 April 2022 EUFOREA will celebrate the launch of the very first Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day in Brussels.
Until now, patients with CRSwNP have had only limited opportunities for their voices to be heard, hence missing the opportunity to contribute to the improvement of CRSwNP care. In 2021, the Patient Advisory Board of EUFOREA published a statement that offered novel insights on the underestimated burden of CRSwNP and shortcomings of current care as well as multiple recommendations for action plans for implementation of better care for CRSwNP among all physicians treating patients with this disabling disease.
The aims of this campaign are:
The background of this article focuses on European patients with chronic rhinosinusitis with nasal polyps (CRSwNP) that have had only limited occasions to unite to have their voices heard, hence missing the opportunity to contribute to the improvement of CRSwNP care.
Uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis, as is typically characterized by a type 2 inflammatory reaction and by comorbidities, including asthma, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease and allergies.
© All rights reserved. EUFOREA – European Forum for Research and Education in Allergy and Airway Diseases.